Patient Buzz Series: Safety of RF Microneedling
A review in Cosmopolitan addressed questions about the safety of radiofrequency (RF) microneedling. Last fall, the FDA issued a safety communication about potential risks with “certain uses” of the devices. The FDA received reports that some RF microneedling patients were burned, scarred, or disfigured, or experienced fat loss or nerve damage. In the article, beauty director Lauren Balsamo sha …
A review in Cosmopolitan addressed questions about the safety of radiofrequency (RF) microneedling. Last fall, the FDA issued a safety communication about potential risks with “certain uses” of the devices. The FDA received reports that some RF microneedling patients were burned, scarred, or disfigured, or experienced fat loss or nerve damage. In the article, beauty director Lauren Balsamo sha … Continue reading "Patient Buzz Series: Safety of RF Microneedling"
New research is supporting the use of two innovative products for acne: a triple combination therapy and the first new molecule for acne in 40 years. In this Next Steps in Derm interview, in partnership with the ODAC Dermatology Conference, Brooklyn, N.Y., dermatologist Dr. Hilary Baldwin outlines the latest acne studies and how these new treatments are helping dermatology clinicians address the f … 
At the 2026 ODAC Dermatology conference, Dr. Adam Friedman opened his session on prurigo nodularis (PN) with a patient case that felt familiar to many of us. A patient with multiple nodules, relentless itch, and one central question. Why is this happening?
This patient case reminds us that prurigo nodularis is not simply the result of scratching or a sequela of another inflammatory disease. It … 
At the 2026 ODAC Dermatology Conference, we had the privilege of learning about chronic spontaneous urticaria (CSU) from Dr. Adam Friedman, MD, FAAD, Professor and Chair of Dermatology at The George Washington University School of Medicine. CSU can be a maddening, exhausting condition for patients, with a relapsing disease course and without identifiable triggers. Given that symptoms are often abs … 
Tacrolimus and Pimecrolimus are both calcineurin inhibitors FDA-approved for atopic dermatitis. However, their topical use offers steroid-sparing benefits for a wide variety of other inflammatory dermatologic conditions. Tacrolimus was discovered in 1984 from the soil bacterium Streptomyces tsukubaensis and was originally FDA approved in 1994 as a systemic immunosuppressant for organ transplanta …